US Patent

US12186362 — Vasopressin formulations for use in treatment of hypotension

Formulation · Assigned to Par Pharmaceuticals Inc · Expires 2035-01-30 · 9y remaining

Vulnerability score 43/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects peptide formulations that use polymers as stabilizing agents to decrease degradation of the peptides.

USPTO Abstract

Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

Drugs covered by this patent

Patent Metadata

Patent number
US12186362
Jurisdiction
US
Classification
Formulation
Expires
2035-01-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Par Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.